

Department of Biological Standardisation, OMCL Network &
HealthCare (DBO)

SR/mha

Working document, with no legally binding status,
intended exclusively for the addressees and their
associates, under the responsibility of the addressees
(listed opposite). Level 2

English / Anglais

PA/PH/CD-P-PH (23) 7 R1

Strasbourg, November 2023

EUROPEAN COMMITTEE ON PHARMACEUTICALS AND PHARMACEUTICAL CARE
(PARTIAL AGREEMENT) (CD-P-PH)

Methodological Guide to Select Medicines at Risk of Shortage - Terms of Reference

19th Meeting

Strasbourg, 19-20 September 2023

Distribution

For action :

CD-P-PH European Committee on Pharmaceuticals and Pharmaceutical Care

For information :

Elaboration of a Methodological Guide for Selecting Medicines at Risk of Shortage during Public Health Emergencies

Terms of Reference (ToR) of the Methodological Guide Working Group

Type of committee

Subordinate working group of the European Committee on Pharmaceuticals and Pharmaceutical Care (CD-P-PH)

Terms of reference valid from: 1 January 2024 until 31 December 2025

Main tasks and expected results

Under the authority of the CD-P-PH, the Methodological Guide Working Group (hereinafter referred to as the Working Group) will draft a methodological guide for identifying and selecting medicines at risk of shortage during public health emergencies that can be prepared as standardised stock preparations (deliverable no. 13 of the CD-P-PH 2022-2025 ToR). This guide will support national competent authorities and healthcare professionals in the identification and selection of medicines that can be in short supply under certain circumstances (e.g. public health emergencies) and that can be prepared in hospital and/or community pharmacy settings, taking into account applicable standards established by international and/or national organisations. In addition, the methodological guide may be used by the working group in charge of developing the European Shortages Formulary (i.e. a compilation of texts (monographs) describing methods for the preparation and quality control of standardised, unlicensed pharmaceutical preparations that could be used as a temporary replacement when licensed medicinal products are unavailable and whose active substances are not affected by a shortage).

Composition

Members: national competent authorities (NCAs) of the states parties and states with observer status to the Convention on the Elaboration of a European Pharmacopoeia are invited to nominate a representative belonging to relevant health authorities or institutions dealing with medicine shortages at national level. To ensure alignment and synergy with other authorities working on shortages, the Heads of Medicines Agencies (HMA)/European Medicines Agency (EMA) Task Force on Availability of authorised medicines for human and veterinary use (TF AAM), the Medicine Shortages Single Point of Contact Working Party (SPOC WP) and the EU Structured dialogue on security of medicines supply are also invited to nominate a representative. To ensure broad expertise and effectiveness, relevant healthcare professionals' associations and academia are also invited to do so.

Desirable qualifications of the Working Group members: ideally, Working Group members should have expertise in one of the following domains: public health, pharmaceutical regulation, medicine shortages or pharmacy preparations.

Validation of the list of Working Group members: the Working Group will be composed of up to 12 members. The final list of members will be reviewed and approved by the EDQM Secretariat.

Secretariat: the EDQM will provide the technical, administrative and scientific secretariat for the Working Group.

Working methods

The Working Group will carry out its programme of activities using scientific and public health-oriented approaches.

With a view to avoiding duplication of work and taking advantage of synergies, the Working Group will take due account of initiatives carried out at international and European level in the area of medicine shortages and, where appropriate, will establish co-operation with stakeholders working in this field (such co-operation may also take the form of a consultation).

The Working Group will make use of virtual meetings and e-mail communication and, when needed, face-to-face meetings.

The Working Group will appoint a rapporteur from among its members who will be responsible for ensuring and contributing to appropriate co-ordination of the Working Group (in concert with the Secretariat) and for interacting and liaising with the CD-P-PH.

Where appropriate, progress towards the Working Group's goal will be presented by the rapporteur at meetings of the CD-P-PH for comment and endorsement. The final deliverable will be submitted to the CD-P-PH for approval prior to publication.

Where appropriate, the Working Group will liaise with and ensure alignment with the work of the working group in charge of developing the European Shortages Formulary.

Budgetary information

The EDQM will bear the travel and subsistence expenses for the Working Group members' participation in one face-to-face meeting per year. When an NCA or stakeholder designates more than one member, the travel and subsistence expenses of only one representative will be covered by the EDQM.